What is NAFLD/NASH?

[madman]

 

[madman]

 

[madman]

Highly Successful Weight Loss Drug Semaglutide Explained - Excel Male TRT Forum

A transcript of this podcast and more information about Tom Wadden is available on the website of the Duke World Food Policy Center at https://wfpc.sanford.duke.edu/podcast... Much attention has been paid recently in both scientific circles and in the media to a drug for weight loss newly...

www.excelmale.com

 

[madman]

 

[madman]

 

[madman]

 

[madman]

 

[madman]

 

[madman]

Oral Prodrug of Testosterone Fast-Tracked for Nonalcoholic Steatohepatitis - Excel Male TRT Forum

https://www.empr.com/home/news/drugs-in-the-pipeline/oral-prodrug-of-testosterone-fast-tracked-for-nonalcoholic-steatohepatitis/ The Food and Drug Administration (FDA) has granted Fast Track designation to LPCN 1144 for the treatment of noncirrhotic nonalcoholic steatohepatitis (NASH). LPCN...

www.excelmale.com

LPCN 1144 Presentation-LiFT Topline 36 Week Results - Excel Male TRT Forum

www.excelmale.com

LPCN 1144 LiFT 12 Week Study Results - Excel Male TRT Forum

www.excelmale.com

LPCN 1144 for Pre-Cirrhotic NASH - Excel Male TRT Forum

www.excelmale.com

LPCN 1148 Oral T (Testosterone Tridecanoate) for Liver Cirrhosis - Excel Male TRT Forum

www.excelmale.com

LPCN1144: LiFT (Liver Fat Intervention with Oral Testosterone) - Excel Male TRT Forum

https://journey.ct.events/view/4e2b1d60-430e-4af3-8c5d-9f4ed7ad6012

www.excelmale.com

Present Clinical Data on oral T (LPCN 1144) at 2022 NASH-TAG Conference - Excel Male TRT Forum

https://www.sec.gov/Archives/edgar/data/1535955/000149315221026815/ex99-4.htm LPCN 1144 IMPROVES BODY COMPOSITION IN BIOPSY-CONFIRMED NASH PATIENTS Background: Non-alcoholic Steatohepatitis (NASH) is a common cause of liver disease and rapidly rising to be the leading indication for liver...

www.excelmale.com

Oral Testosterone for NASH: Open-Label Extension Study Results - Excel Male TRT Forum

https://www.prnewswire.com/news-releases/lipocine-announces-positive-lpcn-1144-nash-open-label-extension-study-results-301545697.html LPCN 1144 was well tolerated over 72-week exposure with no observed safety signals Liver injury markers were reduced and maintained with extended LPCN 1144...

www.excelmale.com

 

[madman]

 

[madman]

 

[madman]